# A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)

> **NCT00127192** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 363 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** sitagliptin phosphate
- **DRUG:** Comparator: placebo (unspecified)

## Key facts

- **NCT ID:** NCT00127192
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 363 (ACTUAL)
- **Last updated:** 2015-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00127192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00127192, "A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00127192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*